Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities

被引:4
作者
Deng, Wei [1 ]
Yang, Zhao [2 ]
Dong, Xin [1 ]
Yu, Rong [1 ]
Wang, Weihu [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China
关键词
adjusted conditional survival; esophageal cancer; multimodality therapy; SEER database; time‐ dependent effect; PERIOPERATIVE CHEMOTHERAPY; FOLLOW-UP; SURGERY; CHEMORADIOTHERAPY; ADENOCARCINOMA; CARCINOMA; PATTERN; EPIDEMIOLOGY; SURVEILLANCE; PROBABILITY;
D O I
10.1002/cam4.3651
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background To estimate the adjusted conditional overall survival (COS) in patients with esophageal cancer after receiving various treatment modalities via a national population-based database, and to investigate the possible time-dependent effects. Materials and Methods Eligible patients diagnosed with esophageal cancer between 2000 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry. The Kaplan-Meier method was used to calculate conventional survival time. The inverse probability of treatment weighting method was used to estimate the adjusted COS in patients receiving different treatment modalities. Landmark analysis was employed to investigate the possible time-dependent effects of different treatment modalities in patients who had survived a certain period of time. Results A total of 25,232 patients were included in the final analysis. The conventional 5-year overall survival was 19.3%. The 5-year adjusted COS increased most for the first 3 years, and increased slightly afterwards. In patients with regional esophageal or gastroesophageal junction cancer, stage-specific analysis showed that surgery only and preoperative radiation therapy benefited most for patients with localized disease, preoperative radiation therapy plus surgery benefited regional, and preoperative radiation therapy plus surgery benefited distant disease, with the 5-year adjusted COS given patients had survived 3 years being 67.0% (95% CI 65.2%-68.7%), 59.9% (95% CI 58.3%-61.5%), 58.4% (95% CI 56.3%-60.5%), and 61.8% (95% CI 59.5%-64.1%), respectively. In time-dependent analysis, the benefits of surgery only in localized cases were prominent within 48 months after diagnosis. Preoperative radiation therapy showed long-lasting benefits in patients with regional disease. In patients with distant disease, all treatment modalities showed similar and short-term effects. Conclusions The adjusted COS in patients with esophageal cancer increased as time accrued after receiving various treatment modalities. The time-dependent effects in specific tumor stage provided a dynamic view on optimization of treatment strategies.
引用
收藏
页码:659 / 674
页数:16
相关论文
共 50 条
[1]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[2]   Adjusted survival curves with inverse probability weights [J].
Cole, SR ;
Hernán, MA .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2004, 75 (01) :45-49
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[5]   Landmark Analysis at the 25-Year Landmark Point [J].
Dafni, Urania .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (03) :363-U216
[6]  
Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO
[7]  
2-L
[8]   Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy [J].
Dresner, SM ;
Griffin, SM .
BRITISH JOURNAL OF SURGERY, 2000, 87 (10) :1426-1433
[9]   Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer A SEER Database Analysis [J].
Dubecz, Attila ;
Gall, Isabell ;
Solymosi, Norbert ;
Schweigert, Michael ;
Peters, Jeffrey H. ;
Feith, Marcus ;
Stein, Hubert J. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) :443-447
[10]   Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial [J].
Fuchs, Charles S. ;
Doi, Toshihiko ;
Jang, Raymond W. ;
Muro, Kei ;
Satoh, Taroh ;
Machado, Manuela ;
Sun, Weijing ;
Jalal, Shadia I. ;
Shah, Manish A. ;
Metges, Jean-Phillipe ;
Garrido, Marcelo ;
Golan, Talia ;
Mandala, Mario ;
Wainberg, Zev A. ;
Catenacci, Daniel V. ;
Ohtsu, Atsushi ;
Shitara, Kohei ;
Geva, Ravit ;
Bleeker, Jonathan ;
Ko, Andrew H. ;
Ku, Geoffrey ;
Philip, Philip ;
Enzinger, Peter C. ;
Bang, Yung-Jue ;
Levitan, Diane ;
Wang, Jiangdian ;
Rosales, Minori ;
Dalal, Rita P. ;
Yoon, Harry H. .
JAMA ONCOLOGY, 2018, 4 (05)